期刊论文详细信息
Microbial Cell Factories
Development of an automated platform for the optimal production of glycoconjugate vaccines expressed in Escherichia coli
Jasmin J. Samaras1  Martina Micheletti1  Marta Mauri2  Brendan W. Wren2  Emily J. Kay2 
[1] Advanced Centre for Biochemical Engineering, University College London, Bernard Katz Building, Gower Street, WC1E 6BT, London, UK;Department of Infection Biology, London School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, London, UK;
关键词: Automation;    Screening studies;    PGCT;    Bioconjugation;    Glycoconjugate vaccine;    Pneumococcal vaccine;    High throughput process development;    Glycoprotein;    Glycoengineering;   
DOI  :  10.1186/s12934-021-01588-1
来源: Springer
PDF
【 摘 要 】

Protein Glycan Coupling Technology (PGCT) uses purposely modified bacterial cells to produce recombinant glycoconjugate vaccines. This vaccine platform holds great potential in this context, namely due to its modular nature, the simplified production process in comparison to traditional chemical conjugation methods, and its amenability to scaled-up operations. As a result, a considerable reduction in production time and cost is expected, making PGCT-made vaccines a suitable vaccine technology for low-middle income countries, where vaccine coverage remains predominantly low and inconsistent. This work aims to develop an integrated whole-process automated platform for the screening of PGCT-made glycoconjugate vaccine candidates. The successful translation of a bench scale process for glycoconjugate production to a microscale automated setting was achieved. This was integrated with a numerical computational software that allowed hands-free operation and a platform adaptable to biological variation over the course of a production process. Platform robustness was proven with both technical and biological replicates and subsequently the platform was used to screen for the most favourable conditions for production of a pneumococcal serotype 4 vaccine candidate. This work establishes an effective automated platform that enabled the identification of the most suitable E. coli strain and genetic constructs to be used in ongoing early phase research and be further brought into preclinical trials.

【 授权许可】

CC BY   

【 预 览 】
附件列表
Files Size Format View
RO202107076017463ZK.pdf 4349KB PDF download
  文献评价指标  
  下载次数:14次 浏览次数:9次